117 related articles for article (PubMed ID: 9273428)
1. [The decisive steps cost billions. Extensive studies provide answers for many questions].
Wallström A; Rosén A; Keisu M
Lakartidningen; 1997 Jul; 94(30-31):2653-7. PubMed ID: 9273428
[No Abstract] [Full Text] [Related]
2. How pharmacogenomics will impact the federal regulation of clinical trials and the new drug approval process.
Binzak BA
Food Drug Law J; 2003; 58(1):103-27. PubMed ID: 12739592
[No Abstract] [Full Text] [Related]
3. [The GCP directive--consequences for clinical drug research].
Gluud CN
Ugeskr Laeger; 2003 Apr; 165(16):1662-4. PubMed ID: 12756824
[TBL] [Abstract][Full Text] [Related]
4. Curbing industry sponsor's incentive to design post-approval trials that are suboptimal for informing prescribers but more likely than optimal designs to yield favorable results.
Falit BP
Seton Hall Law Rev; 2007; 37(4):969-1049. PubMed ID: 18363220
[No Abstract] [Full Text] [Related]
5. Quality assurance in phase II and III studies.
Wood DJ
Qual Assur; 1993 Dec; 2(4):353-8. PubMed ID: 7952970
[TBL] [Abstract][Full Text] [Related]
6. Differences in adverse drug reactions in phase III and phase IV of the drug evaluation process.
Linden M
Psychopharmacol Bull; 1993; 29(1):51-6. PubMed ID: 8378512
[TBL] [Abstract][Full Text] [Related]
7. From translational research to a large randomized clinical trial: a long and streanuous way from bench to bedside.
Sakamoto J; Morita S
Nagoya J Med Sci; 2007 Jan; 69(1-2):9-16. PubMed ID: 17378175
[TBL] [Abstract][Full Text] [Related]
8. Overhauling clinical trials.
Scott CT; Baker M
Nat Biotechnol; 2007 Mar; 25(3):287-92. PubMed ID: 17344876
[No Abstract] [Full Text] [Related]
9. Clinical research: outlook from industry.
Echols R
Clin Perform Qual Health Care; 1996; 4(2):113-4. PubMed ID: 10156942
[No Abstract] [Full Text] [Related]
10. Questions about questions.
Spaight BM
J Altern Complement Med; 2006 Apr; 12(3):235-6. PubMed ID: 16729413
[No Abstract] [Full Text] [Related]
11. [Ethics problems in phase IV of drug studies].
Traversa G; Bignami G
Ann Ist Super Sanita; 1998; 34(2):203-8. PubMed ID: 9810742
[TBL] [Abstract][Full Text] [Related]
12. Drug research: from the idea to the product.
Kuhlmann J
Int J Clin Pharmacol Ther; 1997 Dec; 35(12):541-52. PubMed ID: 9455711
[TBL] [Abstract][Full Text] [Related]
13. Design and endpoints of clinical trials in hepatocellular carcinoma.
Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
[TBL] [Abstract][Full Text] [Related]
14. Rationale and design of the enoximone clinical trials program.
Lowes BD; Shakar SF; Metra M; Feldman AM; Eichhorn E; Freytag JW; Gerber MJ; Liard JF; Hartman C; Gorczynski R; Evans G; Linseman JV; Stewart J; Robertson AD; Roecker EB; Demets DL; Bristow MR
J Card Fail; 2005 Dec; 11(9):659-69. PubMed ID: 16360960
[TBL] [Abstract][Full Text] [Related]
15. Clinical data gap between phase III clinical trials (pre-marketing) and phase IV (post-marketing) studies: evaluation of etanercept in rheumatoid arthritis.
Farahani P; Levine M; Gaebel K; Thabane L
Can J Clin Pharmacol; 2005; 12(3):e254-63. PubMed ID: 16278497
[TBL] [Abstract][Full Text] [Related]
16. Clinical trials and tribulations. Spiraling costs threaten gridlock.
Malakoff D
Science; 2008 Oct; 322(5899):210-3. PubMed ID: 18845742
[No Abstract] [Full Text] [Related]
17. Some design issues in trials of microbicides for the prevention of HIV infection.
Fleming TR; Richardson BA
J Infect Dis; 2004 Aug; 190(4):666-74. PubMed ID: 15272392
[TBL] [Abstract][Full Text] [Related]
18. Clinical trials.
Farrington P; Miller E
Methods Mol Med; 2003; 87():335-52. PubMed ID: 12958466
[No Abstract] [Full Text] [Related]
19. Importance and challenges of studying marketed drugs: what is a phase IV study? Common clinical research designs, registries, and self-reporting systems.
Glasser SP; Salas M; Delzell E
J Clin Pharmacol; 2007 Sep; 47(9):1074-86. PubMed ID: 17766697
[TBL] [Abstract][Full Text] [Related]
20. Designing phase III or IV trials for vaccines: choosing between individual or cluster randomised trial designs.
Vaucher P
Vaccine; 2009 Mar; 27(13):1928-31. PubMed ID: 19368773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
